Introduction {#Sec1}
============

Cyanobacteria inhabit all prevalent terrestrial and aquatic environments \[[@CR43]\] and are a rich source of structurally diverse bioactive compounds \[[@CR37]\]. Cyanobacteria can form toxic blooms \[[@CR38]\], but are also a promising source of potential anticancer agents \[[@CR40]\] and possibly of immunosuppressive compounds \[[@CR27], [@CR31], [@CR44]\].

The bloom-associated toxins (see \[[@CR7], [@CR38], [@CR42]\] for reviews) attack several organs, depending on the nature of their cellular target, like the neurotoxic anatoxins, depending on preferential uptake into particular cells, like the hepatotoxic microcystins, or primary contact with specific organs, like the dermatotoxin lyngbyatoxin. It should be noted that microcystins, if introduced into cells, are able to induce rapid death of all mammalian cells \[[@CR12]\]. Toxic blooms are also associated with the production of more general cytotoxins like cylindrospermopsin \[[@CR18]\]. The bloom-associated toxins are commonly detected by the acute mouse bioassay, which is widely used to monitor drinking and recreational waters to prevent human and animal fatalities \[[@CR6], [@CR7]\].

Isolation of bioactive compounds from field collections is problematic, since re-collection of the field sample is needed if an interesting compound is present in minuscule amounts. In addition, the true producer of a bioactive compound can be difficult to identify, since field collections of cyanobacteria are often an assemblage of multiple organisms. On the other hand, established cyanobacterial culture collections constitute a sustainable source of axenic culturable cyanobacteria and a reliable resource for bioactive compounds, making such collections important within research and bioprospecting \[[@CR9]\]. Bioactive compounds isolated from cyanobacteria have potential as pharmaceuticals with diverse applications \[[@CR3], [@CR19]\]. So far, the most promising drug candidates from cyanobacteria are directed against cancer cells, several cyanobacterial compounds or derivatives thereof being in clinical or preclinical trials against solid cancers \[[@CR30], [@CR35]\].

The present study was undertaken to obtain an overview of the apoptosis-inducing activity against T-cell lymphoma and acute myelogenic leukemia (AML) cells in cultured cyanobacteria, especially in relation to other bioactivities (e.g., mouse toxicity and protein phosphatase inhibition). In addition to providing information about the effect of long-term culturing and the frequency of apoptogens in cyanobacteria from diverse climates, habitats, and genera, the study shows the potential of cyanobacterial culture collections as a resource for immunosuppressive and anti-leukemic drugs.

Materials and methods {#Sec2}
=====================

Laboratory cultures and field samples {#Sec3}
-------------------------------------

The cyanobacterial strains used in the investigation (Table [1](#Tab1){ref-type="table"}A) are maintained in the NIVA Culture Collection of Algae \[[@CR9]\]. The classification and nomenclature of the relevant strains are according to the prevailing taxonomic systems \[[@CR4], [@CR22], [@CR23]\]. The strains were grown in 1.5 l Z8 medium \[[@CR24]\] at 20°C on a shaking table that was illuminated by fluorescent lamps (Philips Tl 65 W/33) at an intensity of 60 μmol photons m^−2^ s^−1^. Cyanobacterial biomass was harvested by centrifugation at 8,000 × *g* for 10 min, lyophilized, and kept at −80°C until extraction. Larger-scale production was in vertical tubular photobioreactors with injection of compressed air-CO~2~ mixture. Biomasses from natural cyanobacterial populations in seven selected inland lakes were collected during bloom conditions. The material represents species from five genera (Table [1](#Tab1){ref-type="table"}B).Table 1Origin and mouse toxicity of the cyanobacterial material screenedA. Cyanobacterial strains from the NIVA Culture Collection of AlgaeSpeciesNIVA strainIsolatedGeographical locationBiotopeMouse toxicity^a^Order: *Chroococcales* *Chroococcus* sp.CYA 3301995HolmestrandfjordenSE. NorwayMarine Fjord-- *Cyanobium* sp.CYA 2301987Östra KyrksundetÅlandEutrophic laken.d. *Cyanosarcina* sp.CYA 3861996Plattenberg BaySouth AfricaSeepage watern.d. *Cyanothece* sp.CYA 3041991River AtnaMid. NorwayLotic biotopen.d. *Cyanothece aeruginosa*CYA 258/21990Queen Maud\'s LandAntarcticaGravel, soiln.d *Merismopedia punctata*CYA 161970L. SteinsfjordSE. NorwayMesotrophic laken.d. *Microcystis aeruginosa*CYA 571978L. FrøylandsvatnW. NorwayEutrophic lakeH *Microcystis aeruginosa*CYA 1431984L. AkersvatnSE. NorwayEutrophic lake-- *Microcystis aeruginosa*CYA 160/11985L. AkersvatnSE. NorwayEutrophic lakeT *Microcystis aeruginosa*CYA 228/11987L. AkersvatnSE. NorwayEutrophic lakeH *Microcystis aeruginosa*CYA 4752003L. VictoriaUgandaEutrophic laken.d *Microcystis aeruginosa*CYA 4762004L. VictoriaUgandaEutrophic laken.d *Microcystis aeruginosa*CYA 4772003L. VictoriaUgandaEutrophic laken.d *Microcystis aeruginosa*CYA 4782003L. VictoriaUgandaEutrophic laken.d *Microcystis botrys*CYA 2641990L. FrøylandsvatnW. NorwayEutrophic laken.d. *Microcystis* cf. *novacekii*CYA 4312000L. VictoriaUgandaEutrophic laken.d. *Microcystis* cf. *wesenbergii*CYA 172/51985L. ArresøDenmarkEutrophic laken.d. *Microcystis ichthyoblabe*CYA 2791990L. ØstensjøvatnSE. NorwayEutrophic lake-- *Microcystis viridis*CYA 122/21983L. FinjasjönS. SwedenEutrophic laken.d. *Synechococcus* sp.CYA 3791996SognefjordW. NorwayMarine fjordn.d. *Synechococcus* sp.CYA 3881996HadelandstjernSE. NorwayFreshwatern.d. *Synechococcus elongatus*CYA 1871985Queen Maud\'s LandAntarcticaDetritusn.d. *Synechococcus nidulans*CYA 20\<1973No informationTOrder: *Nostocales* *Anabaena circinalis*CYA 821980L. SteinsfjordSE. NorwayMesotrophic lake-- *Anabaena flos*-*aquae*CYA 269/61990L. FrøylandsvatnW. NorwayEutrophic lakeH *Anabaena lemmermannii*CYA 83/11980L. EdlandsvatnW. NorwayMesotrophic lakeH *Anabaena lemmermannii*CYA 281/11990L. StoravatnW. NorwayOligotrophic lake-- *Anabaena lemmermannii*CYA 2981990L. StoravatnW. NorwayOligotrophic lake-- *Anabaena spiroides*CYA 3581996L. BalatonHungaryMesotrophic lakeT *Anabaena subcylindrica*CYA 3231993FuggdalenE. NorwayMinerval springn.d. *Anabaenopsis arnoldii*CYA 135/21984L. TurkanaKenyaGreat Rift Valley Lake-- *Aphanizomenon gracile*CYA 3381994L. BalatonHungaryMesotrophic lake-- *Aphanizomenon* cf*. klebahnii*CYA 3721996L. BalatonHungaryMesotrophic laken.d. *Cylindrospermopsis raciborskii*CYA 2251984L. BalatonHungaryMesotrophic lakeT *Cylindrospermopsis raciborskii*CYA 3991997L. BalatonHungaryMesotrophic lakeT *Cylindrospermum* sp*.*CYA 2451988SpydebergSE. NorwayAgricultural soiln.d. *Dichothrix* sp*.*CYA 5182004Disko IslandGreenlandMelt water puddlen.d. *Nodularia* cf*. harveyana*CYA 227\<1986No information-- *Nostoc* sp.CYA 1241983L. SteinsfjordSE. NorwayMesotrophic lake-- *Nostoc* sp.CYA 1951985Queen Maud\'s LandAntarcticaLotic biotope-- *Nostoc* sp.CYA 2951990Ny ÅlesundSpitsbergenLimestone graveln.d. *Nostoc* sp.CYA 3081990Ny ÅlesundSpitsbergenEpiphytic on mossT *Nostoc* sp.CYA 3091990Ny ÅlesundSpitsbergenEpiphytic on mossn.d. *Nostoc* sp.CYA 5122004Disko IslandGreenlandMelt water puddlen.d. *Nostoc* sp.CYA 5202005SpydebergSE. NorwayGarden pooln.d. *Scytonema* sp.CYA 3451993Queen Maud\'s LandAntarcticaGravel, soil--Order: *Oscillatoriales* *Arthrospira* sp.CYA 447n.d.L. ParacasPeruFreshwater(T) *Leptolyngbya foveolarum*CYA 541975SpydebergSE. NorwayAir sample-- *Limnothrix redekei*CYA 1061982L. MälarenSwedenEutrophic laken.d. *Lyngbya major*CYA 1731987Kajiki, KagoshimaJapanGarden pondn.d. *Oscillatoria curviceps*CYA 1491984BjørndalenSpitsbergenMelt water-- *Phormidium breve*CYA 761956DaxSW. FranceLaken.d. *Phormidium* sp.CYA 1811985Queen Maud\'s LandAntarcticaSandfieldT *Phormidium* sp.CYA 1841985Queen Maud\'s LandAntarcticaMelt waterT *Phormidium* sp.CYA 2031984CoraholmenSpitsbergenMoraine soilT *Phormidium* sp.CYA 2101985GrumantSpitsbergenBoggy soil-- *Phormidium* sp.CYA 3151993Lier, BuskerudSE. NorwayGreenhouse soil-- *Phormidium* sp.CYA 4481990EidsvollSE. NorwaySeepage watern.d. *Phormidium* sp.CYA 4542000SandebuktaSE. NorwayMarine fjordn.d. *Phormidium* cf. *formosum*CYA 1101977River SakaJapanLotic biotopen.d. *Phormidium* cf. *subfuscum*CYA1771985Queen Maud\'s LandAntarcticaGravel, soilT *Phormidium formosum*CYA 921981L. LevrasjönS. SwedenMesotrophic lakeN *Planktothrix agardhii*CYA 211973Gulf of FinlandSE. FinlandBrackish water-- *Planktothrix agardhii*CYA 291968L. GjersjøenSE. NorwayEutrophic lakeH *Planktothrix agardhii*CYA 1161983L. ÅrungenSE. NorwayEutrophic lake-- *Planktothrix agardhii*CYA 1261984L. LångsjönÅlandDystrophic lakeH *Planktothrix agardhii*CYA 1271984L. VesijärviFinlandEutrophic laken.d. *Planktothrix agardhii*CYA 111964L. AkersvatnSE. NorwayEutrophic lakeH *Planktothrix rubescens*CYA 4061998L. SteinsfjordSE. NorwayMesotrophic laken.d. *Planktothrix rubescens*CYA 981982L. SteinsfjordSE. NorwayMesotrophic lakeH *Planktothrix rubescens*CYA 97/31982L. SteinsfjordSE. NorwayMesotrophic lakeH *Planktothrix rubescens*CYA 4071998L. SteinsfjordSE. NorwayMesotrophic laken.d. *Prochlorothrix* sp.CYA 8/901990L. MälarenE. SwedenEutrophic lakeT *Pseudanabaena* sp.CYA 931981L. GjersjøenSE. NorwayEutrophic lake-- *Pseudanabaena* sp.CYA 941982River GlåmaSE. NorwayLotic biotope-- *Pseudanabaena* sp.CYA 1671968Lough NeaghN. IrlandEutrophic lake-- *Pseudanabaena* sp.CYA 4352000L. VictoriaUgandaEutrophic laken.d. *Pseudanabaena* sp.CYA 4522000SandebuktaSE. NorwayMarine fjordn.d. *Pseudanabaena limnetica*CYA 801976L. WindermereEnglandMesotrophic lakeT *Pseudanabaena limnetica*CYA 276/61990L. MälarenE. SwedenEutrophic laken.d. *Symploca* sp.CYA 3161993Lier, BuskerudSE. NorwayGreenhouse soil-- *Tychonema bornetii*CYA 114/11983River GlåmaSE. NorwayLotic biotope-- *Tychonema bourrellyi*CYA 33/11976L. MjøsaSE. NorwayMesotrophic lakeTB. Natural cyanobacteria populations from Norwegian inland waters collected during bloom conditionsDominant speciesNatural sampleIsolatedGeographical locationBiotopeMouse toxicity^a^*Anabaena lemmermannii*NWS 431992L. StoravatnW. NorwayOligotrophic lakeT*Anabaena lemmermannii*NWS 441991L. StoravatnW. NorwayOligotrophic lakeN*Aphanizomenon* cf. *flos*-*aquae*NWS 461998L. AkersvatnSE. NorwayEutrophic lakeT*Microcystis aeruginosa*NWS 481988L. FrøylandsvatnW. NorwayEutrophic lakeH*Phormidium* cf. *formosum*NWS 451990Dammenbekken, LarvikNorwayBrookH*Planktothrix agardhii*NWS 491991L. KalvsjøtjernMid. NorwayEutrophic lakeH*Planktothrix agardhii*NWS 511980L. HelgetjernSE. NorwayEutrophic/mixotrophic--^a^Code mouse bioassay: *H* hepatotoxic, *T* toxicity, *N* neurotoxic, -- not toxic, *n.d.* not determined

Mouse bioassay {#Sec4}
--------------

Female mice (Bom:NMRI) weighing 15--25 g were fed ad libitum on standard chow and treated in accordance with Norwegian law and FELASA guidelines. For toxicity testing, 50 mg of lyophilized cyanobacterial biomass was suspended in 1 ml of sterile 0.9% NaCl solution and injected intraperitoneally. Routinely, each extract was tested on two mice. Symptoms were observed and registered during the following 48 h. Hepatotoxicity and neurotoxicity were judged as previously described \[[@CR1], [@CR39]\].

Extraction of cyanobacterial biomass {#Sec5}
------------------------------------

Extraction of cyanobacterial biomass for analytical purposes was performed as described \[[@CR17]\]. Briefly, 20 mg of freeze-dried cyanobacterial biomass was extracted sequentially in water (A extract), 70% aqueous methanol (B extract), and 1/1 (v/v) methanol:dichloromethane (C extract). The extracts were dried in a centrifugal vacuum concentrator and resuspended in 0.2 ml of water (A and B extract) or in 0.05/0.15 (v/v) ml of DMSO/water (C extract).

Cell culturing and experimental conditions {#Sec6}
------------------------------------------

IPC-81 rat promyelocytic leukemia suspension cells \[[@CR25]\] were cultured in Dulbecco's modified Eagle\'s medium (EuroClone^®^ Life Sciences Division, Milan, Italy) with 10% (v/v) heat-inactivated horse serum (EuroClone^®^ Life Sciences Division, Milan, Italy). Jurkat human T-cell lymphoma suspension cells (American Type Culture Collection, Rockville, MD, US) were cultured in RPMI 1640 medium (Gibco^®^invitrogen cell culture, Invitrogen AS, Carlsbad, CA, USA) with 10% (v/v) heat-inactivated fetal calf serum (EuroClone^®^ Life Sciences Division, Milan, Italy). Culturing density was between 1 × 10^5^ and 8 × 10^5^ cells/ml and adjusted by dilution in fresh medium every 2--3 days. Cells were incubated at 37°C in a humid atmosphere with 5% CO~2~.

The cells were seeded in 96-well tissue culture plates (0.1 ml cell suspension/well, 1.5 × 10^5^ cells/ml) and incubated with cyanobacterial extracts or vehicle for 18 h, when the cells were fixed (1:1) in 2% buffered formaldehyde (pH 7.4) containing 0.01 mg/ml of the DNA specific fluorescent dye Hoechst 33342 (Sigma-Aldrich, St. Louis, MO, USA).

Primary hepatocytes were isolated from male Wistar rats (80--150 g) by in vitro collagenase perfusion as previously described \[[@CR29], [@CR33]\]. The experimental conditions were as described in \[[@CR17]\].

Scoring of apoptotic and necrotic cell death was by microscopic (Axiovert 35 M, Zeiss) evaluation of surface and nuclear morphology \[[@CR17], [@CR32], [@CR41]\]. Each extract was tested in triplicate at dilutions from a starting point corresponding to 4 mg original dryweight biomass/ml (4 mg/ml), and the LC~50~ (concentration needed to induce 50% cell death) determined (Table [2](#Tab2){ref-type="table"}A, B). The extract apoptogenicity was classified as high (LC~50~ \< 2 mg/ml), intermediate (LC~50~: 2--4 mg/ml), low (LC~50~ \> 4 mg/ml; 25--49% death at 4 mg/ml), or as absent (\<25% cell death at 4 mg/ml). The potency of extracts from various cyanobacterial orders and genera was compared by two-way ANOVA, and least significance difference post hoc tests with the SPSS software (Chicago, IL, USA).Table 2Potency of cyanobacterial extracts to induce cell death in myelogenic leukemia cells and T-lymphoma cellsA. Cyanobacterial strains from the NIVA Culture Collection of AlgaeSpeciesNIVA strainMyelogenic leukemia cells (IPC-81)^a^T-lymphoma cells (jurkat)^a^A extractB extractC extractA extractB extractC extractOrder: *Chroococcales* *Chroococcus* sp.CYA 330----------2.8 ± 0.04 *Cyanobium* sp.CYA 230----2.8 ± 0.17\>4\>41.9 ± 0.06 *Cyanosarcina* sp.CYA 386------------ *Cyanothece* sp.CYA 304------\>4\>4\>4 *Cyanothece aeruginosa*CYA 258/2------------ *Merismopedia punctata*CYA 16\>4----4.0 ± 0.21\>4-- *Microcystis aeruginosa*CYA 572.4 ± 0.11------1.6 ± 0.492.3 ± 0.41 *Microcystis aeruginosa*CYA 1432.6 ± 0.11--------\>4 *Microcystis aeruginosa*CYA 160/1--------\>4\>4 *Microcystis aeruginosa*CYA 228/10.34 ± 0.00------2.5 ± 0.102.8 ± 0.11 *Microcystis aeruginosa*CYA 475\>4----\>41.39 ± 0.151.27 ± 0.11 *Microcystis aeruginosa*CYA 476\>4--2.83 ± 0.222.50 ± 0.12\>4\>4 *Microcystis aeruginosa*CYA 4772.46 ± 0.16----2.05 ± 0.252.34 ± 0.38\>4 *Microcystis aeruginosa*CYA 4782.60 ± 0.12--\>4\>4--2.16 ± 0.13 *Microcystis botrys*CYA 2640.49 ± 0.05\>4--3.8 ± 0.18---- *Microcystis* cf. *novacekii*CYA 431--------\>4-- *Microcystis* cf. *wesenbergii*CYA 172/50.73 ± 0.03----0.32 ± 0.00--2.4 ± 0.52 *Microcystis ichthyoblabe*CYA 2790.37 ± 0.00--2.5 ± 0.110.23 ± 0.02\>41.8 ± 0.07 *Microcystis viridis*CYA 122/20.71 ± 0.032.5 ± 0.12--\>4--\>4 *Synechococcus* sp.CYA 379----------\>4 *Synechococcus* sp.CYA 3883.0 ± 0.21------2.4 ± 0.152.2 ± 0.03 *Synechococcus elongatus*CYA 1872.4 ± 0.22---------- *Synechococcus nidulans*CYA 20--------\>42.6 ± 0.05Order: *Nostocales* *Anabaena circinalis*CYA 822.4 ± 0.16\>4--\>4--\>4 *Anabaena flos*-*aquae*CYA 269/60.24 ± 0.01\>4--0.36 ± 0.002.1 ± 0.433.2 ± 0.59 *Anabaena lemmermannii*CYA 83/1\>4---------- *Anabaena lemmermannii*CYA 281/10.52 ± 0.03----0.89 ± 0.16--2.6 ± 0.17 *Anabaena lemmermannii*CYA 2980.66 ± 0.01----1.0 ± 0.002.2 ± 0.05-- *Anabaena spiroides*CYA 358------------ *Anabaena subcylindrica*CYA 3232.3 ± 0.37--2.5 ± 0.14\>4--2.2 ± 0.08 *Anabaenopsis arnoldii*CYA 135/20.67 ± 0.01----2.2 ± 0.03\>4-- *Aphanizomenon gracile*CYA 3380.92 ± 0.17\>4--\>4--\>4 *Aphanizomenon* cf. *klebahnii*CYA 3721.7 ± 0.28--------\>4 *Cylindrospermopsis raciborskii*CYA 2250.59 ± 0.12--4.1 ± 0.122.5 ± 0.11--2.5 ± 0.13 *Cylindrospermopsis raciborskii*CYA 3990.93 ± 0.052.5 ± 0.11\>42.0 ± 0.123.3 ± 0.022.4 ± 0.15 *Cylindrospermum* sp.CYA 2452.4 ± 0.19--\>4----4.1 ± 0.61 *Dichothrix* sp.CYA 518------------ *Nodularia* cf. *harveyana*CYA 227\>4---------- *Nostoc* sp.CYA 124\>4----\>4--2.5 ± 0.13 *Nostoc* sp.CYA 195----------\>4 *Nostoc* sp.CYA 2951.5 ± 0.04----2.5 ± 0.11\>42.4 ± 0.15 *Nostoc* sp.CYA 308------------ *Nostoc* sp.CYA 309------------ *Nostoc* sp.CYA 512------------ *Nostoc* sp.CYA 520------\>4---- *Scytonema* sp.CYA 345----------\>4Order: *Oscillatoriales* *Arthrospira* sp.CYA 4471.0 ± 0.03----2.5 ± 0.11---- *Leptolyngbya foveolarum*CYA 542.8 ± 0.112.5 ± 0.11------\>4 *Limnothrix redekei*CYA 1062.3 ± 0.122.5 ± 0.11----3.1 ± 0.04\>4 *Lyngbya* cf. *major*CYA 173----1.7 ± 0.08----2.2 ± 0.09 *Oscillatoria curviceps*CYA 1492.2 ± 0.13--------\>4 *Phormidium breve*CYA 763.0 ± 0.08---------- *Phormidium* sp.CYA 181\>4---------- *Phormidium* sp.CYA 184------------ *Phormidium* sp.CYA 2032.1 ± 0.12------\>42.5 ± 0.14 *Phormidium* sp.CYA 210------\>4---- *Phormidium* sp.CYA 315----------3.4 ± 0.58 *Phormidium* sp.CYA 448------\>4---- *Phormidium* sp.CYA 454------------ *Phormidium* cf. *formosum*CYA 1102.0 ± 0.07----2.5 ± 0.132.4 ± 0.15-- *Phormidium* cf. *subfuscum*CYA177----------\>4 *Phormidium formosum*CYA 921.1 ± 0.13----2.5 ± 0.122.5 ± 0.142.4 ± 0.14 *Planktothrix agardhii*CYA 21\>4----\>4--\>4 *Planktothrix agardhii*CYA 291.9 ± 0.02--------3.8 ± 0.74 *Planktothrix agardhii*CYA 116\>4----2.5 ± 0.10---- *Planktothrix agardhii*CYA 1262.8 ± 0.17---------- *Planktothrix agardhii*CYA 1271.8 ± 0.07--4.1 ± 0.492.5 ± 0.10--2.7 ± 0.45 *Planktothrix agardhii*CYA 112.4 ± 0.05----\>4---- *Planktothrix rubescens*CYA 406\>4----2.3 ± 0.10---- *Planktothrix rubescens*CYA 982.1 ± 0.17----3.0 ± 0.16---- *Planktothrix rubescens*CYA 97/33.5 ± 0.26--------3.2 ± 0.46 *Planktothrix rubescens*CYA 407------\>4--\>4 *Prochlorothrix* sp.CYA 8/902.3 ± 0.11----2.5 ± 0.102.5 ± 0.14-- *Pseudanabaena* sp.CYA 932.6 ± 0.12\>4----2.9 ± 0.30\>4 *Pseudanabaena* sp.CYA 940.85 ± 0.14------2.3 ± 0.162.1 ± 0.17 *Pseudanabaena* sp.CYA 1671.9 ± 0.152.5 ± 0.10--3.9 ± 0.29\>4-- *Pseudanabaena* sp.CYA 435\>4---------- *Pseudanabaena* sp.CYA 4522.8 ± 0.33---------- *Pseudanabaena limnetica*CYA 800.91 ± 0.12------2.4 ± 0.181.8 ± 0.13 *Pseudanabaena limnetica*CYA 276/62.4 ± 0.29------\>43.1 ± 0.41 *Symploca* sp.CYA 3163.1 ± 0.10---------- *Tychonema bornetii*CYA 114/12.2 ± 0.18\>4----3.5 ± 0.11\>4 *Tychonema bourrellyi*CYA 33/10.52 ± 0.03\>4--2.1 ± 0.032.5 ± 0.122.5 ± 0.13B. Natural cyanobacteria populations from Norwegian inland waters collected during bloom conditionsDominant speciesNatural sampleMyelogenic leukemia cells (IPC-81)^a^T-lymphoma cells (jurkat)^a^A extractB extractC extractA extractB extractC extract*Anabaena lemmermannii*NWS 43--\>4------2.7 ± 0.53*Anabaena lemmermannii*NWS 44--2.5 ± 0.13----\>44.0 ± 0.60*Aphanizomenon* cf. *flos*-*aquae*NWS 46--2.5 ± 0.13------3.1 ± 0.11*Microcystis aeruginosa*NWS 482.0 ± 0.162.4 ± 0.11----\>42.4 ± 0.12*Phormidium* cf. *formosum*NWS 453.2 ± 0.25\>4--\>4--\>4*Planktothrix agardhii*NWS 49\>4------4.0 ± 0.28\>4*Planktothrix agardhii*NWS 512.4 ± 0.13------2.7 ± 0.04\>4^a^Cells were incubated with various concentrations of cyanobacterial extracts (*A* aqueous, *B* 70% methanol, *C* methanol:dichloromethane) for 18 h and scored for cell death. Values are concentration (mg original dryweight biomass/ml) of extract required to induce 50% death (mean ± SEM, *n* = 3). \>4 signifies 25--50% cell death at 4 mg dw/ml, and -- signifies \<25% cell death at 4 mg dw/ml

Assay of protein serine/threonine phosphatase 2A (PP2A) activity {#Sec7}
----------------------------------------------------------------

PP2A was purified from rabbit muscle following the previously described protocol \[[@CR8]\]. Protein phosphatase activity was measured by the release of radiolabeled phosphate from \[^32^P\]-labeled phosphohistones as previously described \[[@CR13]\]. In brief, 0.1 ml 50 mM Hepes containing 1 mM EDTA, 0.3 mM EGTA, 0.5 mg/ml BSA, 1 mM DTT, 1.25 mM MnCl~2~ was added either cyanobacterial extract, MC-LR or vehicle together with PP2A (8 nM). \[^32^P\]-histone (500 nM) was then added and samples were left to incubate for 10 min at 30°C before stopping the reaction by addition of TCA to 7%. The supernatant was added 0.15 ml 1 N H~2~SO~4~ containing 1 mM K~2~HPO~4~ and 0.2 ml 6% ammonium heptamolybdate in 1.4 N H~2~SO~4~. After 5 min of incubation, 0.6 ml of isobutanol was added and samples were vortexed and centrifuged at 1,100 × *g* for 2 min. The isobutanol fractions were collected and measured for content of \[^32^P\] by liquid scintillation.

Purification of apoptosis-inducing compounds: extraction, solid phase extraction (SPE), and reversed phase high performance liquid chromatography (HPLC) {#Sec8}
--------------------------------------------------------------------------------------------------------------------------------------------------------

Biomass (300 mg dryweight) was added to 25 ml water (4°C) and homogenized 6 × 30 s pulses (Polytron^®^Typ PT10/35, Kinematica, Switzerland). The homogenate was incubated 2 h on ice in the dark before centrifugation (40,000 × *g* for 15 min) and washing with 12.5 ml of water.

The strong anion exchange SPE cartridge (Sep-Pak^®^Accell™Plus QMA; 360 mg; Waters Corporation, Milford, USA) was conditioned with 5.5 ml of methanol, equilibrated with 5.5 ml of water, loaded with 1 ml of water extract (corresponding to 6 mg original dryweight biomass), and washed with 2.5 ml water. The load and wash eluates were pooled.

Analytes in the non-retained fractions from the anion-exchange SPE of the cyanobacterial strains CYA 225, CYA 399, CYA 94, or CYA 80 were separated on a reversed phase chromatography column with nonpolar endcapping (Kromasil^®^KR100-5-C18; 250 × 4.6 mm) coupled to a Merck-Hitachi LaChrom HPLC system (VWR, West Chester, USA) with a L-7455 diode array detector. The flow rate was 0.8 ml/min and a 6-min run in isocratic mode with 94/6 (v/v %) water/acetonitrile was followed by a 24-min linear gradient to 100% acetonitrile. Analytes in selected HPLC fractions were further separated isocratically with water as solvent on a reversed phase column with polar endcapping (Aquasil C18; 150 × 3 mm) at a flow rate of 0.5 ml/min.

Mass spectrometry (MS) {#Sec9}
----------------------

Mass spectrometry was performed on a Quadrupole Time-of-Flight (Q-ToF) Ultima Global Mass spectrometer (Micromass, Manchester, UK) equipped with a nanoflow z-spray source. Compounds in 0.5% formic acid were infused into the mass spectrometer at a flow rate of 1--2 μl/min. MS spectra were acquired in positive ion electrospray mode with a source temperature at 80°C and a capillary voltage of 3 kV. MS/MS analysis was with collision energy of 20--40 V, but otherwise had similar parameters.

Results and discussion {#Sec10}
======================

Apoptosis-inducing activity is frequent in cyanobacteria and is independent of their geographical origin {#Sec11}
--------------------------------------------------------------------------------------------------------

The cyanobacterial strains studied represented 27 genera from the orders *Chroococcales*, *Nostocales*, and *Oscillatoriales* harvested from various biotopes located in areas spanning polar, via temperate to tropical geographical zones (Table [1](#Tab1){ref-type="table"}A). Seven natural populations from Norwegian freshwater blooms (Table [1](#Tab1){ref-type="table"}B) were also studied. To assess the apoptogenic activity in the cyanobacteria, extracts of decreasing polarity were tested against jurkat T-cell lymphoma and IPC-81 rat promyelogenic leukemia cells. The jurkat T-cells are widely used to screen for immunosuppressive agents \[[@CR5], [@CR14], [@CR21], [@CR34]\], whereas the IPC-81 cells originate from the BNML rat model, which is used for studying human AML and is known to be a reliable predictor of the potential of anti-leukemic drugs (reviewed by \[[@CR28]\]). Unlike normal cells of the myeloid lineage the IPC-81 cells can be grown in conventional medium, have very little spontaneous apoptosis \[[@CR16], [@CR25]\], and are sensitive to commonly used anti-leukemic drugs \[[@CR15]\]. These cells were therefore used to assess the presence of compounds with potential to be developed as drug candidates for acute myelogenic leukemia. Both cell lines were exposed for 18 h to aqueous (A), 70% methanol (B), or dichloromethane/methanol (C) extracts of the cyanobacterial strains/populations. All but 18 of the 90 cyanobacterial samples showed apoptogenic activity towards the T-cell lymphoma (Table [2](#Tab2){ref-type="table"}). Nine of them induced apoptosis with high potency, and 41 with intermediate potency (Table [2](#Tab2){ref-type="table"}). We detected apoptogenic activity against AML cells in all but 23 of the 90 cyanobacteria samples tested. Twenty-two of them induced apoptosis with high potency, and 32 with intermediate potency (Table [2](#Tab2){ref-type="table"}).

We reasoned that the variety of genera, geographical zone of origin, and biotope would reveal any correlation between these parameters and the expression of apoptosis-inducing activity in vitro. Much of the past research has been into identification of bioactive cyanobacterial compounds from tropical and sub-tropical environments. We found no correlation between the apoptogenic activity and the geographical location where the cyanobacteria had been sampled (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}). However, we noted that there was a correlation between cyanobacterial genera and the amount of apoptogenic activity; the seven strains with the most potent activity against T cells were all from the genera *Microcystis* (4) or *Anabaena* (3). In contrast, these genera accounted for only two of the 18 non-apoptogenic strains (Table [2](#Tab2){ref-type="table"}). The genera *Anabaena* and *Microcystis* had also more anti-leukemic activity than *Nostoc*, *Phormidium*, *Planktothrix*, and *Pseudanabaena* (*p* \< 0.05).

In conclusion, the apoptosis-inducing activity appears to be abundant in cyanobacteria, in particular of the genera *Microcystis* or *Anabaena*, and is independent of geographical localization.

The apoptosis-inducing activity did not correlate with the outcome of the mouse toxicity assay {#Sec12}
----------------------------------------------------------------------------------------------

The present cyanobacterial culture collection has been created mainly to chart potentially toxic blooms and 47 of the selected strains and all the natural populations had been tested in the mouse bioassay just after their isolation. Of the tested strains, 24 were negative (no toxicity observed 48 h after injection) and 30 were positive (56%). Of the positive samples, two induced signs of neurotoxicity, 12 caused liver damage, and 16 exhibited toxicity that could not be described as neurotoxic or hepatotoxic (Table [1](#Tab1){ref-type="table"}). The outcome of the mouse bioassay was similar between *Chroococcales* (14 positive, 12 negative) and *Oscillatoriales* (16 positive, 12 negative).

By comparing the content of apoptogens against T-cell lymphoma and AML-cells and with the outcome of the mouse bioassay we expected to reveal if toxin-producing cyanobacteria were more or less likely to produce other cell death-inducing compounds. No overall correlation was observed between the outcome of the mouse bioassay and content of apoptogenic activity against either cell line (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}). The lacking predictive value of the mouse bioassay is illustrated by comparing the nine extracts with the strongest anti-T-cell lymphoma activity with the 18 non-apoptogenic extracts. Of the isolates in the first group, three of the six tested in the mouse assay were positive, while five of the seven isolates tested in the second group were positive (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}). The same was observed regarding the anti-AML activity. Among the 22 samples with high apoptogenic activity, 16 had been tested by mouse bioassay, and of these, nine were positive, while of the 23 without apoptogenic activity, 11 had been tested in mouse bioassay and six of these were positive (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}).

Still, we considered whether microcystin or similarly acting protein phosphatase inhibitors could be responsible for some of the anti-AML activity in the aqueous extracts, since these toxins target major protein phosphatases that are abundant in all eukaryotic cells. The hepatocytes are primary targets due to their efficient microcystin uptake \[[@CR11], [@CR26]\], but other cells can also be targeted at higher concentration of microcystin \[[@CR2]\], and microinjected microcystin induces apoptosis within a few minutes in all mammalian cells tested \[[@CR12]\]. We found that the LC~50~ for microcystin-LR was 200 μM for the T-cell lymphoma and 150 μM for the AML cells and we have previously shown that microcystins have a 20-fold higher apoptosis-inducing activity towards hepatocytes than towards leukemia cells, even if the leukemia cells were incubated with toxin for 18 h compared to the 1-h incubation of hepatocytes \[[@CR17]\]. Twelve of the extracts with the highest anti-AML activity were therefore assayed for content of microcystin-like activity by the PP2A assay and some were also analyzed by HPLC/MS (Table [3](#Tab3){ref-type="table"}). The anti-AML activity did not correlate with the microcystin content, which, as expected, correlated closely with hepatotoxicity in the mouse bioassay and the induction of apoptosis in primary hepatocytes (Table [3](#Tab3){ref-type="table"}). The lower-than-expected activity of *Microcystis* CYA 264 towards hepatocytes could be explained by the content of a novel nostocyclopeptide inhibitor of microcystin-induced hepatocyte apoptosis \[[@CR20]\]. Furthermore, the extract with the highest PP2A inhibitory content would maximally contribute 13 μM microcystin to the AML cells, and the type of apoptotic cell death observed (not shown) differed from the one induced by protein phosphatase inhibitors, which typically induce strongly polarized blebbing in various cell types \[[@CR12]\].Table 3Content of phosphatase inhibitor, toxicity to mice and apoptosis induction in hepatocytes, and AML cells in cyanobacterial extractsSpeciesNIVA strainMC-LR equivalents (μM)MicrocystinToxic to miceApoptosis induction in primary hepatocytesApoptosis induction in AML cells*Microcystis aeruginosa*CYA 228/1930+H++++++++*Microcystis botrys*CYA 2641300+n.d.++++++*Microcystis* cf. *wesenberghii*CYA 172/53.5−n.d.−++++*Microcystis ichthyoblabe*CYA 279\<0.1−--−++++*Microcystis viridis*CYA 122/24.0−n.d−++++*Anabaena flos*-*aquae*CYA 269/6270+H++++++++*Anabaena lemmermannii*CYA 281/1\<0.1n.d.--−++++*Cylindrospermopsis raciborskii*CYA 225\<0.1n.d.T−++++*Cylindrospermopsis raciborskii*CYA 399\<0.1n.d.T−++++*Pseudanabaena* sp.CYA 940.3n.d.--−++++*Pseudanabaena limnetica*CYA 80\<0.1n.d.T−++++*Tychonema bourrellyi*CYA 33/13.6n.d.T−++++Water extracts from 12 cyanobacterial isolates were assayed for content of PP2A inhibitory activity and expressed as MC-LR equivalents. Toxicity to mice and the presence of microcystin was determined in some strains by HPLC and MS. Induction of apoptosis in AML cells and primary hepatocytes by the 12 water extracts was also investigated. The scores signify: −, \<10% apoptosis; +, 10--25% apoptosis; ++, 25--50% apoptosis; +++, 50--75% apoptosis; ++++, 75--100% apoptosis

We conclude that the apoptogenic activity against T-cell lymphoma and/or AML-cells could not be ascribed to known phosphatase inhibitors and that the mouse bioassay has little ability to predict the presence of AML and T-cell apoptogens. This is not unexpected if the apoptogens are targeted against the immune system or the myeloid lineage of the hematopoetic system, since life-threatening symptoms from the elimination or paralysis of these cells will not be apparent during the short period of the acute mouse bioassay. A negative response in the mouse bioassay predicts a lack of acutely acting toxins, and this might therefore be a positive trait in the search for therapeutic lead compounds.

Cyanobacterial apoptogen diversity resulted from differences between strains and the presence of more than one activity in the same strain {#Sec13}
------------------------------------------------------------------------------------------------------------------------------------------

Several of the cyanobacteria contained more than one apoptogenic compound, since activity was detected in both the aqueous (A) and the organic (C) extract, whereas no activity was detected in the intermediate methanol (B) extract (Table [2](#Tab2){ref-type="table"}). In addition, A and C extracts often produced apoptosis with different phenotypes (not shown).

Apoptogens against AML cells were about as prevalent as apoptogens against T-lymphoma cells. However, apoptosis-inducing activity towards AML cells was almost completely confined to the aqueous (A) extracts, whereas the apoptosis-inducing activity towards T-lymphoma cells were generally found in the organic extract (Table [2](#Tab2){ref-type="table"}). Interestingly, we found that several strains contained both activities. For instance, the *Planktothrix strains* CYA 29 and 97/3 contained an apoptogen specific towards AML cells in the aqueous (A) extract and another apoptogen specific towards T-cell lymphoma cells in the organic (C) extract. In addition, two strains, *Microcystis* CYA 228/1 and *Anabaena* CYA 269/6, were proven to contain hepatotoxic microcystin in addition to apoptogens specific towards T-cell lymphoma and/or AML-cells (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}).

Based on the difference in polarity of the A extract and C extract, we conclude that the apoptosis-inducing activity against T-cell lymphoma and AML-cells often resided in different molecules.

The biosynthetic production of apoptogenic compounds are preserved in cyanobacteria even after long-term culturing {#Sec14}
------------------------------------------------------------------------------------------------------------------

A potential problem in bioprospecting is the loss of biosynthetic capability for the substances of interest upon culturing of the producing organism. We noted apoptogenic activity in strains maintained in culture for several years (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}). For instance, *Phormidium* CYA 76, isolated in 1956, exhibited apoptosis-inducing activity and *Microcystis* CYA 264, isolated in 1990, produced substantial amounts of microcystin. When we compared the apoptogenicity of old and recent cultures, we found no indications that the recently collected strains contained more apoptogens than the formerly collected. This suggests that the cyanobacteria maintain their original biosynthetic capability after isolation and culturing, and underlines the importance of culture collections.

To further study the apoptogenic activity in some of the highly potent anti-AML extracts (Table [3](#Tab3){ref-type="table"}), we performed bio-guided isolation of the water extract. After extraction and anion-exchange solid-phase extraction the apoptosis-inducing activity was highly recovered (data not shown) in four strains collected at different time-points and locations (CYA225, CYA399, CYA94, CYA80). These four strains had similar HPLC profiles, as shown for CYA94 in Fig. [1](#Fig1){ref-type="fig"}a, as well as toxin profiles (not shown). The anti-AML fraction in the beginning of the chromatogram (Fig. [1](#Fig1){ref-type="fig"}a) was further separated and the apoptosis-inducing activity found to reside in one peak (Fig. [1](#Fig1){ref-type="fig"}b) with a UV-spectrum exhibiting a λ~max~ at 199 nm (Fig. [1](#Fig1){ref-type="fig"}c). This highly polar compound was common for both the *Cylindrospermopsis* strains (CYA 225 and CYA 399) and the *Pseudanabaena* strains (CYA 80 and CYA 94), as determined by retention time, absorbance spectra, and MS analysis. The molecular mass of the compound was 159.3 Da (Fig. [1](#Fig1){ref-type="fig"}d). This mass differs from that of known bloom-associated cyanobacterial toxins. Upon MS/MS, two fragments (*m/z*: 143 and*m/z*: 126) were created, corresponding to the loss of one and two masses of 17 Da (Fig. [1](#Fig1){ref-type="fig"}e). The fragmentation pattern was similar to that seen in some amines \[[@CR36]\].Fig. 1Analysis of apoptosis-inducing compounds by HPLC and mass spectrometry. **a** Analytes in anion-exchange SPE fraction of CYA 94 were separated by reversed phase HPLC. Fractions were collected and tested for the ability to induce cell death in AML cells. A major death-inducing activity eluted in fraction 4 (3--4 min) and was termed 94-4 (*boxed*). **b** The 94-4 fraction was further fractionated by polar endcapped reversed C18 phase HPLC chromatography. The bioactivity (*dotted line*) eluted with a peak with retention time of 1.91 min. **c**--**e** The peak (94-4-1.91) was analyzed by UV spectroscopy (**c**), and mass spectrometry (MS) (**d**) and MS/MS (**e**)

This demonstrates that cultured cyanobacteria, even after long-term culturing under axenic conditions, constitute a renewable source for toxins and interesting apoptogenic compounds.

Concluding remarks {#Sec15}
==================

This study demonstrates that cyanobacteria kept in culture not only give toxicological information but also represent a renewable source for other bioactive compounds.

There was no correlation between mouse toxicity and induction of apoptosis neither in T-cell lymphoma nor in AML-cells, which indicates that cyanobacteria produce a diversity of still uncharacterized bioactive compounds. The present findings indicate that cyanobacteria in addition to production of specific toxins like microcystin, were able to produce high levels of other cell death-inducing compounds, irrespective if collected from blooms or not.

The biosynthetic capability of cyanobacteria \[[@CR10]\] offers an opportunity for finding novel useful compounds, as illustrated by several cyanobacterial anti-cancer agents currently under development \[[@CR30], [@CR35]\]. The negative mouse bioassay for many strains with high content of activity against T-cell lymphoma or AML-cells (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}) is in this context an advantage since it suggests that the compounds have only limited acute toxicity in the intact organism. In fact, 23 cyanobacterial strains and one natural population that were non-toxic to mice contained apoptogens. This suggests that culture collections of cyanobacteria without toxicity against mammals constitute a valuable source for bioactive compounds with pharmaceutical potential.
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